Browse Author: David B.

BONE SCINTIGRAPHY

Diagnosis

Technicium diphosphonate bone scans are extremely valuable in identifying occult lesions and diagnosing metastatic disease. Whereas nearly 30% of bone mineral must be lost for a lesion to appear on plain radiograph, bone scans show disease much earlier. This test (1) is an essential part of cancer staging for skeletal metastases, (2) identifies sites of symptomatic disease, and (3) identifies potential sources of referred pain. Certain cancers such as lung and melanoma grow rapidly and evoke little reactive bone formation, leading to false-negative scans. Multiple myeloma is also notorious for having false-negative bone scans.
Treatment Evaluation

Bone scan can be used to evaluate the response to chemotherapy, hormone therapy, or radiation therapy. Much more sensitive than plain radiographic evaluation, it reflects the biology of the lesion and the extent of the host response. The method has been most useful in evaluating the treatment of breast cancer patients. Up to 15% of patients will have an initial increase in activity, the so-called flare phenomenon. This reflects new bone formation around the quiescent lesion. Over time, the surrounding bone can heal, and osteoblast activity, estimated by the bone activity, will diminish. Development of “new” scintigraphic lesions early in treatment does not necessarily reflect disease progression; sometimes it reflects healing and ossification of areas where the tumor did not evoke a response initially.
Canadian Pharmacy levitra
One limitation of this technique is that it merely measures metabolic activity and does not evaluate the structural integrity of the skeleton. Biologic control of the tumor does not translate into mechanical restoration of the skeleton in all cases. Therefore, the bone scan findings must be evaluated in parallel with plain radiographs, CT scan, or both.

Radioimmunoisotope scanning holds promise to improve both the sensitivity and specificity of bone scans in patients with metastatic disease. As better, humanized antibodies become available, both the diagnosis of occult disease and the monitoring of established disease will become more reliable. Preliminary results in imaging breast cancer metastases are encouraging.
COMPUTED TOMOGRAPHY
Computed tomography is very effective in evaluating the three-dimensional integrity of bone and to better visualize abnormal lesions identified on bone scan. This is helpful to confirm the presence of metastatic disease, particularly when evaluating tumors in the pelvic and shoulder girdles. Spine lesions can also be seen by CT, but are probably better evaluated by magnetic resonance imaging (MRI) in most circumstances. In all locations CT demonstrates the bone mineral content and cortical integrity better than MRI, at present. These characteristics thus reflect the structural integrity of the diseased bone. Commonly MRI will show extensive marrow involvement in a bone while the structural strength is preserved. CT helps to discriminate between the presence of cellular and structurally significant disease.

RADIOGRAPHIC IMAGING OF METASTASES

RADIOGRAPHY

Radiographs are the fastest, least expensive, and most readily available technique to diagnose metastases. Even though other techniques may be more sensitive, the radiograph gives the best integration of overall bone structure and alignment. It remains the cornerstone for evaluation of the mechanical properties of bone and correlates best with clinical features. It should therefore be the first test ordered in the evaluation of pain. Radiographs greatly assist surgical planning. The ease of measuring and monitoring lesions makes the plain radiograph indispensable.

Disease spreads diffusely within long bones. A frequent problem occurs in patients with proximal femoral metastases in whom radiographic evaluation is confined to the hip and potential lesions distal in the femur are overlooked. It is very important to image the entire bone before internal fixation so that all lesions can be stabilized during the same operative procedure.

Metastatic disease is characterized by the presence of multiple bone lesions. Single metastases occur rarely and must be differentiated from primary bone tumors. Typically, the so-called “solitary metastasis” is merely the first of many lesions to be identified. Thyroid and renal cancers and myeloma (plasmacytoma) are the most likely to present as isolated metastases. Even these favorable cases typically develop widespread disease, suggesting that there is unrecognized dissemination of cancer at the time the first bone metastasis is identified.

There are three typical radiographic patterns of metastatic disease: osteolytic, osteoblastic, and mixed. Because of variations in the bone microenvironment and clonal differentiation of tumors, different patterns may exist throughout the skeleton or within one bone. This is also seen during the course of therapy, where one lesion may be partially treated. Osteoblastic areas seen radiographically correspond to the reaction of the host bone to the metastases. They are not the cancer itself. Fast-growing tumors tend to have a mixed pattern where bone reaction cannot keep up with the tumor rate of growth. The reactive bone often lacks mechanical strength despite its deceptively strong appearance. It forms in a random pattern lacking Haversian structure. Just as in Paget’s disease, disorganized sclerotic bone can be weak and incur fracture.

Periosteal changes may occur for several reasons. Rapidly growing tumor can elevate the periosteum, causing an irregular periosteal reaction. Lung cancer and prostate cancer with cortical involvement commonly show this pattern. Stress fracture through the underlying bone can also be associated with periosteal elevation. Nevertheless, periosteal elevation is usually a hallmark of primary bone neoplasm. Sarcoma should be excluded when there is periostitis.

Bone cancer. Treatment goals

TREATMENT GOALS

Pain relief and bone stabilization are the methods by which the medical goals of patient comfort and independence are achieved. Symptomatic relief is usually satisfactory from radiation therapy and chemotherapy. Most patients without a fracture do not require surgery for the bone metastasis. Fractures are best treated by operative internal fixation. Even when fractures can heal by nonoperative therapy, the protracted treatment time is inappropriate. The duration of any treatment must be carefully considered in a patient with a limited life expectancy. For example, in a patient with a 4-month life expectancy, 2 weeks of treatment for bone metastases may be appropriate, whereas 2 months of treatment would be excessive. Finally, the goal of surgical intervention is to allow immediate weight bearing. If this cannot be achieved, then surgery should be avoided. Prosthetic replacement and stabilization with polymethylmethacrylate are frequently selected, whereas such techniques would be avoided in the treatment of nonneoplastic fractures.

Generally, pathologic fractures through weight-bearing bones (e.g., femur) should be treated if the patient has more than 1 month to live, whereas non-weight-bearing bones should be treated if life expectancy is more than 3 months. Indications for treating impending fractures are discussed later. Impending fractures are worth fixing if it will help eliminate the need for narcotic analgesics or will reduce the patient’s overall pain by approximately 50%, and equally effective nonoperative treatments are lacking.

Bone cancer

Pain is the principal symptom of bone metastases. It is composed of a biologic and a mechanical aspect. The biologic component reflects the rate of tumor growth and biologic characteristics of the tumor. The increased blood flow and cytokines are important causes of bone pain and contribute to bone lysis. Finally, nerves within bone have recently been described; these transmit many neuropeptides such as substance P and calcitonin gene-related protein, which are involved in both pain modulation and bone metabolism.

Bone loss reduces bone strength and stiffness, increases strain, and leads to activity-related symptoms: so-called “mechanical bone pain.” Pain from mechanical insufficiency often increases after a treatment reduces turgor within the tumor. Bone collapse and even dislocation can then occur. This is seen most often in “successful” treatment of spinal lesions. Late sequelae such as osteonecrosis and fatigue fracture are other manifestations of mechanical insufficiency.

The initial pain pattern of a metastasis mimics that of primary bone tumors and osteonecrosis. The symptoms are intermittent but may be sharp and severe. Pain tends to be worst at night and maybe partially relieved by activity. As the lesions progresses, symptoms become more constant and take on more of a mechanical character.
General systemic issues are of concern in patients with skeletal metastases. Bed rest or reduced activity is frequently recommended for the bone pain of skeletal metastases. This produces general disuse and weakness. Manifestations commonly include atelectasis and thromboembolic disease. Careful screening for these conditions is imperative. Doppler ultrasound tests are convenient and sensitive to identify deep vein thrombosis. Loss of ambulatory ability is a poor prognostic factor in metastatic disease, particularly spine disease. Performance status should be specifically quantified as part of the preoperative evaluation.
DIAGNOSIS

Plain radiography remains the most specific test to diagnose bone diseases. Scintigraphy is extremely sensitive and practical because it can screen the entire body at one time. Certainly, any abnormality found on bone scan should be assessed with plain radiographs. Only when the diagnosis cannot be discerned from clinical information and these baseline tests should magnetic resonance imaging (MRI) be obtained.

Solitary bone lesions warrant a biopsy before treatment. Primary bone sarcomas occur in the population particularly under consideration. Lytic phases of dedifferentiated chondrosarcoma and Paget’s sarcoma can also produce pathologic fractures. These must not be confused with the pathologic fractures of metastatic disease. A firm diagnosis must be obtained before internally fixing such a fracture.

CT-guided needle biopsy is usually satisfactory when the lesion is osteolytic (diagnostic accuracy, 80%). When the lesion is osteoblastic or there is a thick overlying cortical rim, it is extremely difficult to insert a needle and obtain an adequate tissue sample. Such cases necessitate open surgical biopsy. Whether the biopsy is performed by closed or open technique, fracture risk is worsened by the new hole in the bone cortex. Weight bearing must be protected until bone healing occurs. Experimentally, this requires at least 6 weeks. Adequate tissue is necessary to perform special studies if required. For example, recently, the spectrum of Ki-1 lymphomas has been noted and these tumors frequently mimic metastatic carcinomas. Sufficient tissue for immunohistochemical studies should always be obtained.

Future directions.

Although uncontrolled studies and anecdotal reports of high-dose chemotherapy with marrow reconstitution appear promising, the highly selected nature of the patients and the expense of the procedures mandate that randomized, comparative trials demonstrate the superiority of this approach over standard therapy before it can be considered a valid part of the therapeutic armamentarium. Such a study is underway with very poor accrual.

Intraperitoneal administration of drug, although under study for over a decade, still has no defined role in management. In the salvage setting, it appears to have no advantage over intravenous therapy. In the setting of first-line treatment, two large randomized trials in patients with small-volume disease show small advantages but have major design problems. The final determination of the role, if any, for intraperitoneal therapy awaits the completion of the current trial comparing intravenous paclitaxel-platinum to intraperitoneal paclitaxel-platinum. If a role for intraperitoneal therapy exists, data show that it will be in only those patients with extremely small-volume disease or perhaps no residual disease; hence, its role will be a very narrow one.
Breast cancer
In conclusion, the future holds the promise of continuing advances in the management of patients with celomic epithelial carcinoma of the ovary. Although the explosion of knowledge of the basic nature of the disease holds the greatest potential for improvement, the identification of an effective screening technique, the clarification of the role of surgery in advanced disease, and the introduction of exciting new agents such as Taxol offer the promise of better treatment in the immediate future. The great promise of dose-intense regimens, still worthy of further investigation, suffers from a growing body of evidence that no advantage is obtained at least over the clinically achievable range of doses unsupported by marrow reconstitution.

FUTURE DIRECTIONS. Fallopian Tube Cancer

Third, although the efficacy of initial surgical cytoreduction in patients with stage III disease has been accepted on the basis of retrospective analyses, prospective trials are needed to address several important questions. One such study suggests an advantage for interval surgical cytoreduction at the midpoint of a series of chemotherapy courses. Prospective randomized trials of initial or secondary surgical cytoreduction have not been completed. Investigations of the relative merits of each of these approaches versus no surgery are needed, as well as trials evaluating which of these points in the therapy represents the optimal time to introduce surgical resection into the management of advanced disease. Such studies are difficult to conduct because of the widespread acceptance of the role of surgical cytoreduction in ovarian carcinoma. A confirmatory trial of interval cytoreduction is nearing completion, but further study is needed.

Fourth, efforts continue to investigate the role of new agents in the management of ovarian carcinoma. Current interest continues to center on further delineation of the role of paclitaxel. The plethora of new agents with activity in patients who are clinically resistant to the platinum compounds and paclitaxel, however, opens the possibility for the addition of clinically non-cross-resistant drugs to front-line paclitaxel-platinum therapy. Defining the role of these new agents is of paramount importance.

Finally, dose intensity continues to command significant interest. Three basic ways to enhance the dose intensity have been proffered: escalation of dose within the range that can be achieved without marrow reconstitution, high-dose chemotherapy with support of autologous bone marrow transplant or peripheral stem cell transfusion, and, in the case of ovarian carcinoma, intraperitoneal administration of drug. Eight randomized trials of dose escalation over a standard range of doses have been completed. Six show no advantage to a doubling of dose intensity, and the other two have major design problems. Further exploration of this approach seems unwarranted.

New Treatments for Fallopian Tube Cancer

FUTURE DIRECTIONS

The development of additional information about the nature and management of germ cell cancers and rarer malignant tumors of the ovary as well as fallopian tube cancer will continue to be restricted by the low frequency of these lesions. With regard to celomic epithelial carcinomas of the ovary, however, progress should continue to be rapid. Current and future investigational efforts focus on several distinct areas: biology of ovarian carcinoma, screening and early detection, the proper role of surgery, new agents and their role in systemic therapy, and the value of approaches to achieve greater dose intensity.
Cheap Levitra Pharmacy
First, with regard to the biology of ovarian carcinoma, specific studies are seeking (1) to characterize factors associated with ovarian carcinoma and its outcome such as specific genetic defects associated with hereditary ovarian carcinoma, various oncogenes, and DNA ploidy; (2) to identify features predictive of the likelihood of developing ovarian carcinoma; and (3) to ascertain the biologic reasons for the observation that more aggressive disease is associated with older patients. As these and other investigations expand the understanding of the basic nature of ovarian carcinoma, the development of better and more specific methods for early detection and treatment of the disease should be possible. Where this line of work will ultimately lead is speculative but exciting.

Second, the evolution of effective techniques for screening for and early detection of ovarian carcinoma has a high priority in ovarian carcinoma, the only one of the major gynecologic cancer for which early detection is not the rule. Most interest centers on the potential for transvaginal sonography, especially when enhanced by color flow Doppler, to permit earlier detection of disease. Studies are currently directed at improving the specificity of the technique and at demonstrating an impact on the morbidity and mortality of the disease. Ultimately, confirmation of the value of the procedure will depend on a large screening trial of high-risk women (one or more first-order relatives), a study now planned but as yet unfunded.